Norovirus: genotypes, tests, course and complications

Norovirus is the leading cause of acute gastroenteritis in people of all ages. It is a highly contagious pathogen, transmitted through contact with an infected person, food, water, and contaminated surfaces. International public health agencies estimate that norovirus accounts for approximately 18% of all cases of diarrhea and vomiting worldwide, with the annual number of cases estimated in the hundreds of millions. [1]

The burden on healthcare systems and the economy is high. According to estimates from specialized centers alone, hundreds of millions of episodes of gastroenteritis and tens of thousands of deaths in young children are recorded annually, primarily in low-resource countries. This makes norovirus a priority target for outbreak prevention and control. [2]

Infection is possible with tiny doses of the virus, but its release into the environment can reach enormous amounts. This explains the ease of spread in closed communities: nursing homes, hospitals, childcare facilities, ships, and restaurants. [3]

In temperate climates, outbreaks most often occur during the cold season, but infection is possible year-round. Immunity after the disease is incomplete and short-lived, predisposing to recurrent episodes, especially when new variants of the pathogen emerge. [4]

In most patients, therapy is supportive and focused on rehydration, correction of electrolyte imbalances, and safe symptom relief. Specific antiviral drugs are not yet approved for routine use; vaccination is in development and is undergoing an important re-evaluation following the unsuccessful trial of a major candidate. [5]

Table: Key facts about norovirus

Parameter	Intelligence
The main clinical form	Acute gastroenteritis with diarrhea and vomiting
Infectious dose	From 18 particles and above
Peak seasonality	Mostly in winter, but there are cases all year round
Main routes of transmission	Contact-household, food, water, aerosol-droplet deposition during vomiting
Basic therapy	Oral rehydration, intravenous solutions if necessary

Epidemiology

The global disease burden remains persistently high. An estimated 685 million episodes occur annually, with approximately 200 million occurring in children under 5 years of age; tens of thousands of deaths are reported in this group. Overall, norovirus is responsible for approximately 18% of acute gastroenteritis cases. [6]

Following declines due to pandemic-related restrictions, many countries in Europe in 2023–2024 reported increases in cases and outbreak levels above pre-pandemic seasons. Increased circulation of genotypes was observed, including outbreaks of GII.17 in several countries. [7]

Transmission is most intense in closed settings, where close contact and surface contamination create conditions for reinfection. In such settings, norovirus contributes significantly to the "winter burden" on health services. [8]

The low infectious dose and persistence of the virus in the environment lead to foodborne outbreaks and contact transmission chains. Even isolated episodes of vomiting can cause aerosols to settle on surrounding surfaces, supporting the spread of the virus into communities. [9]

Prolonged viral shedding after clinical recovery maintains occult transmission. In immunocompromised patients, chronic viral shedding with months-long shedding and intra-host evolution of variants is possible. [10]

Table. Epidemiological guidelines

Indicator	Typical value
Share of all acute gastroenteritis	About 18%
Global cases per year	About 685 million
Vulnerable groups	Children under 5 years of age, elderly, immunocompromised
Seasonality	Mostly cold months
Recent trends in Europe	Activity to pick up in 2023-2024, with the GII share growing.17

Structure of the pathogen

Norovirus belongs to the Caliciviridae family and is an unenveloped particle of icosahedral symmetry with a diameter of approximately 35-50 nanometers. The capsid is composed of the VP1 protein, organized into 90 dimers, and a small amount of VP2 protein. This architecture forms the "envelope" domain and the protruding P-domain, which is critical for receptor recognition on human cells. [11]

The viral genome is a single-stranded, positive-sense ribonucleic acid approximately 7.5 kilonucleotides long with a covalently linked VPg protein at the five-base end. The genome encodes three open reading frames: a large polyprotein of nonstructural proteins and two structural proteins of the capsid. [12]

Critical regions of the P2 subdomain of VP1 interact with so-called blood histogroup antigens on the surface of human cells. The diversity of these carbohydrate structures in humans partially determines susceptibility to different genotypes and increases the virus's maneuverability when new variants emerge. [13]

Nonstructural proteins formed from the polyprotein include protease and RNA-dependent RNA polymerase, as well as proteins that restructure intracellular membranes and create "replication factories." The NS4 protein, for example, is involved in organizing membrane structures necessary for the synthesis of genomic and subgenomic ribonucleic acid. [14]

The capsid structure and the ability to assemble virus-like particles based on VP1 are actively used for vaccine development and the evaluation of neutralizing antibodies. These particles morphologically and antigenically mimic native virions and allow for safe study of immune responses. [15]

Table. Genome and proteins of norovirus

Component	Function
Genomic ribonucleic acid	Matrix for the synthesis of polyprotein and capsid proteins
VPg	Primer and regulator of genomic ribonucleic acid translation
VP1	The main capsid protein forms the S and P domains
VP2	Minor capsid protein, stabilization of genomic packaging
Protease and polymerase	Polyprotein maturation and genome replication

Life cycle

Infection begins with attachment to carbohydrate "targets" on the surface of enterocytes in the small intestine. Interaction of the VP1 P-domain with blood histogroup antigens ensures recognition and entry into the cell. Some genotypes exhibit different binding spectra, which influences tropism and epidemic potential. [16]

After penetration, the genomic ribonucleic acid is immediately translated, forming a polyprotein. The viral protease, at predetermined "cut points," forms a set of nonstructural proteins that restructure the endomembrane compartments. RNA-dependent RNA polymerase operates on these "platforms." [17]

Replication involves the synthesis of a full-length negative copy, then new positive genomes and subgenomic ribonucleic acid for the synthesis of VP1 and VP2. Capsid assembly and genome packaging lead to the maturation of virions, which are released and infect neighboring cells.[18]

Modern models based on human intestinal enteroids have enabled reproducible cultivation of certain norovirus genotypes. This has been a breakthrough for studying the life cycle and screening antiviral candidates, although sensitivity and reproducibility depend on the strain and donor characteristics. [19]

New data on the structure of polymerase, protease, and key nonstructural proteins are clarifying replication bottlenecks potentially suitable for drug targeting. This area is actively developing and links fundamental discoveries with the search for therapeutic targets. [20]

Table. Life cycle stages

Stage	Short description	Potential therapeutic targets
Attachment	Binding to blood histogroup antigens	Blockade of capsid interaction with receptors
Penetration and disassembly	Delivery of the genome into the cytoplasm	Entry inhibitors
Polyprotein translation	Formation of non-structural proteins	Protease inhibitors
Genome replication	Synthesis of new copies of ribonucleic acid	Polymerase inhibitors
Assembly and exit	Formation of virions	Capsid assembly failure

Pathogenesis

The primary target is mature enterocytes of the small intestine. Damage and functional dysregulation of the villi lead to impaired water and electrolyte absorption and secretory diarrhea. The rapid development of symptoms is associated with a massive release of inflammatory mediators and intestinal and gastric motor reflexes. [21]

The virus is extremely stable in the environment: it can survive for weeks on dry surfaces at room temperature. When vomited, the aerosol can spread over a wide area, contaminating objects and flooring. These properties create the "perfect" combination for outbreaks. [22]

Immune protection develops, but is often short-lived and type-specific. Rapid antigenic changes in the capsid protein allow the virus to evade previously formed neutralizing antibodies, which supports the periodic emergence of "successful" variants, such as the waves of GII.4 genotypes and the recent rise of GII.17. [23]

Even after clinical recovery, a person can shed the virus for several weeks. In immunocompromised patients, shedding continues for months and years, is accompanied by intra-population evolution, and can lead to a relapsing course. [24]

The severity of the disease is determined by age, comorbidities, and the volume of fluid loss. Dehydration and electrolyte imbalances contribute most to adverse outcomes, leading to acute renal dysfunction and other complications if not promptly rehydrated. [25]

Table. Key mechanisms of pathogenesis

Mechanism	Significance for the clinic
Enterocyte damage and dysfunction	Impaired absorption of water and electrolytes
Inflammatory mediators	Nausea, vomiting, abdominal pain
Stability in the external environment	Long-term pollution of premises
Antigenic variability	Recurrent infections and outbreaks
Long-term allocation	Prolonged risk of transmission after recovery

Symptoms

The incubation period is usually 12-48 hours. The onset is acute, with nausea, repeated vomiting, watery diarrhea, cramping abdominal pain, weakness, and often low-grade fever. In young children, vomiting may predominate over diarrhea. [26]

Symptoms typically last no more than 1-3 days, but weakness, decreased appetite, and unstable bowel movements may persist longer. Fluid loss depends on the frequency of bowel movements and vomiting and determines the need for medical attention. [27]

Signs of dehydration include thirst, dry mucous membranes, decreased urine output, dizziness, and, in children, a sunken fontanelle, lethargy, and a lack of tears when crying. These symptoms require immediate assessment of the degree of dehydration and rehydration. [28]

In the elderly and in people with chronic diseases, the course may be more severe, with significant electrolyte disturbances. Immunocompromised patients are prone to prolonged diarrhea and weight loss. [29]

Even without severe dehydration, some people who have recovered from the disease develop post-infectious syndrome with impaired intestinal motility and sensitivity, which manifests itself as abdominal pain, bloating, and unstable stool. [30]

Table: Symptoms by age group

Group	Most common manifestations
Children under 5 years old	Repeated vomiting, watery diarrhea, fever, risk of dehydration
Teenagers and adults	Diarrhea and vomiting, cramping pain, weakness
Elderly	Severe dehydration, electrolyte disturbances, drop in blood pressure
Immunocompromised	Prolonged diarrhea, weight loss, prolonged viral shedding

Stages

The course of the disease can be divided into incubation, acute, and recovery phases. The incubation phase lasts from 0.5 to 2 days and is clinically asymptomatic, but primary replication in enterocytes is already underway. [31]

The acute phase typically lasts 1-3 days and is characterized by peak vomiting and stool frequency. During this period, the risk of transmission is highest, as viral shedding is very high. [32]

The recovery phase takes place over the following days. Symptoms subside, appetite and food tolerance are restored, but weakness and unstable stools may persist. [33]

Virus excretion in feces continues after symptoms disappear. In immunocompromised individuals, the excretion phase becomes chronic and requires special monitoring tactics. [34]

In some patients, post-infectious functional symptoms develop after the acute phase. These are not associated with ongoing active inflammation, but can significantly impair quality of life. [35]

Table. Staging of the course

Stage	Duration	Key Features
Incubation	0.5-2 days	Asymptomatic replication
Acute	1-3 days	Maximum vomiting, diarrhea and contagiousness
Restorative	A few days	Reduction of symptoms, maintenance of weakness
Long-term allocation	Weeks and longer	Especially in immunocompromised individuals

Forms

The typical form is acute watery gastroenteritis. A vomiting-predominant form is possible, especially in young children, and a diarrhea-predominant form in adults. These phenotypes determine the clinical tactics of rehydration. [36]

A severe form is observed in the elderly, in people with comorbidities, and when rehydration is initiated late. It is accompanied by profound dehydration, hypovolemia, and electrolyte imbalances. [37]

The protracted and chronic form is typical for patients with immunodeficiency: those who have undergone transplants, those receiving immunosuppression, or those with congenital immune defects. Months and years of viral shedding and significant weight loss are possible. [38]

Foodborne outbreaks often occur in clusters, with symptoms appearing simultaneously in groups of people who shared a common food item. In such situations, rapid investigation, isolation of patients, and disinfection are critical. [39]

In those who have recovered, a post-infectious functional form with symptoms of irritable bowel syndrome is possible, which requires a differentiated approach and an explanation to the patient of the benign nature of the condition. [40]

Table. Clinical forms and management guidelines

Form	Who is it characteristic of?	Leading tactics
Typical acute	Most patients	Oral rehydration, diet as tolerated
Variant with predominant vomiting	More often children	Local application of antiemetics, fractional rehydration
Heavy	Elderly, comorbid	Intravenous solutions, electrolyte monitoring
Chronic in immunocompromised patients	Transplanted and other immunodeficiencies	Long-term observation, correction of immunosuppression, experimental approaches
Post-infectious functional	Some of those who recovered	Education, diet therapy, symptomatic support

Complications and consequences

The main acute complications are related to dehydration and electrolyte imbalances: hyponatremia, hypokalemia, and metabolic changes. Without timely rehydration, acute renal dysfunction, collapse, and seizures in children are possible. [41]

In the elderly, norovirus can trigger decompensation of chronic conditions. In long-term care facilities, outbreaks lead to increased hospitalizations and mortality due to underlying illnesses. [42]

In immunocompromised individuals, prolonged diarrhea with weight loss, hypoproteinemia, and multi-month viral shedding often develops, which requires multidisciplinary monitoring. [43]

Among the long-term consequences, an increased risk of post-infectious functional gastrointestinal disorders, including irritable bowel syndrome and dyspepsia, is discussed. The risk increases in the first months after gastroenteritis. [44]

Finally, prolonged environmental contamination during outbreaks supports secondary cases unless strict cleaning and disinfection requirements at the site are followed. [45]

Table. Main complications and risk factors

Complication	Risk factors	Prevention
Severe dehydration	Children and the elderly, frequent vomiting	Early rehydration
Electrolyte disturbances	Repeated loose stools and vomiting	Electrolyte monitoring in moderate to severe cases
Acute renal dysfunction	Hypovolemia	Intravenous rehydration when indicated
Prolonged diarrhea	Immunodeficiency	Correction of immunosuppression, observation
Post-infectious functional complaints	Any age after a severe episode	Training, diet therapy, medications as indicated

Diagnostics

The "gold standard" of laboratory confirmation is the detection of viral ribonucleic acid by quantitative reverse transcription-polymerase chain reaction in feces. Modern panels allow for the typing of major genotypes and provide an assessment of viral load. [46]

In routine practice, with a typical clinical picture and the presence of an outbreak, laboratory confirmation is not always required, however, in severe cases, hospitalization, outbreaks in institutions and in immunocompromised patients, testing is desirable for epidemiological control and exclusion of other causes. [47]

Rapid immunochromatographic antigen tests are less sensitive than nucleic acid-based methods and are more suitable for indicative assessments when resources are limited. Automated molecular platforms accelerate diagnosis and improve detection rates. [48]

Genotyping is useful for epidemiologists. Dual typing of polymerase and capsid helps track the circulation of recombinants and the change in dominant lineages, which is important for assessing seasonal dynamics. [49]

Instrumental diagnostics are usually not required. Blood tests are aimed at assessing the degree of dehydration and electrolyte imbalances. Imaging methods are indicated only in cases of atypical clinical presentation and suspected surgical pathology. [50]

Table. Laboratory confirmation methods

Method	Pros	Cons	When to choose
Reverse transcription polymerase chain reaction	High sensitivity and specificity, typing	Requires a laboratory	Hospitalization, outbreak, immunodeficiency
Antigen rapid test	Fast and easy	Lower sensitivity	Limited resources
Sequencing of the polymerase and capsid regions	Surveillance, detection of recombinants	Resources are needed	Public health centers

Differential diagnosis

It is important to differentiate norovirus gastroenteritis from rotavirus and sapovirus infections, bacterial diarrhea, parasitic infestations, and non-infectious causes. Clues to norovirus include fulminant onset, a combination of vomiting and watery diarrhea, "familial" and collective clusters, and winter seasonality. Polymerase chain reaction (PCR) can help confirm the diagnosis. [51]

Bacterial infections are often accompanied by fever, blood and mucus, severe pain, and often a longer course. Nucleic acid-based laboratory panels can quickly narrow the cause and avoid unnecessary antibiotics. [52]

In children, surgical causes of vomiting and abdominal pain should be excluded using clinical criteria and, if necessary, referred for imaging. If foodborne illness is suspected, the epidemiological link to a specific product is decisive. [53]

In immunocompromised individuals, it is important to be aware of the possibility of mixed infections and prolonged viral shedding. A more thorough search for causes is necessary in cases of protracted illness and weight loss. [54]

Table: Differences between norovirus gastroenteritis and other causes

Sign	Norovirus	Bacterial diarrhea	Parasitic infestations
Start	Sharp, hours	More often gradual	Gradual
Blood in the stool	Rarely	Often	Rarely
Vomit	Very often	Less often	Sometimes
Duration	Usually 1-3 days	Longer	Often for weeks
Laboratory confirmation	Polymerase chain reaction	Culture or molecular panels	Microscopy and molecular panels

Treatment

The basis of therapy is rehydration. For mild to moderate dehydration, an oral rehydration solution with low osmolarity is preferred. The recommended volume for the first 2-4 hours is 50-100 milliliters per kilogram of body weight, followed by a 10 milliliter per kilogram dose after each episode of loose stool and 2 milliliters per kilogram after an episode of vomiting. Early feeding in small portions accelerates recovery. [55]

In severe dehydration, intravenous rehydration is indicated using standard regimens with monitoring of sodium, potassium, urea, and creatinine. The choice of solutions and the rate of infusion are determined by the severity and associated conditions, especially in the elderly. [56]

To reduce vomiting in children over 6 months of age in emergency settings, a single dose of ondansetron is acceptable. This facilitates oral rehydration and reduces the need for intravenous infusions. Regular course use outside of a hospital setting is not recommended. In adults, short-term symptomatic use under medical supervision is possible, if indicated. [57]

Zinc at a dose of 10-20 milligrams per day for 10-14 days is recommended for children under 5 years of age to reduce the duration and severity of diarrhea, especially in resource-limited settings. Antibacterial drugs are not indicated for norovirus. Probiotics have a conflicting evidence base and are not a mandatory part of therapy. [58]

Specific antiviral therapy remains investigational. Nitazoxanide has been studied in immunocompromised patients but has not yet demonstrated a convincing benefit in systematic models and individual trials. Favipiravir has demonstrated antiviral activity through mutagenesis induction in limited studies but is not approved for the treatment of norovirus. Candidates, such as viral protease inhibitors, are in preclinical and early clinical stages. Their use is only possible within the context of trials and on an individual basis. [59]

Table. Management tactics by severity

Degree	Signs	Tactics
Light	Thirst, moderate weakness, preserved diuresis	Oral rehydration, fractional drinking, nutrition as tolerated
Average	Dry mucous membranes, decreased diuresis, tachycardia	Enhanced oral rehydration, electrolyte assessment, ondansetron as indicated
Heavy	Severe weakness, severe oliguria, orthostatic phenomena	Intravenous fluids, electrolyte monitoring, hospitalization

Prevention

Handwashing with soap remains a key measure. Alcohol-based antiseptics are less effective against norovirus, especially in cases of visibly contaminated surfaces. Cleaning and disinfection of the outbreak requires bleach solutions with a concentration of 1000-5000 parts per million active chlorine, left for at least 5 minutes, and then rinsed. [60]

Food service staff and any workers who come into contact with food are required to remain off work for at least 48 hours after symptoms subside. In outbreak areas, it is recommended to remove common dining areas, restrict patient and staff movement, and intensify cleaning. [61]

Food safety requires washing fruits and vegetables, cooking shellfish, preventing cross-contamination, and strict personal hygiene. In the case of isolated vomiting, extensive disinfection of the area around the episode is necessary. [62]

Vaccine prophylaxis is in development. The most advanced candidate, based on virus-like particles, HIL-214, failed to meet the primary and secondary efficacy endpoints in a large study in infants, leading to the program's closure. Work on other platforms continues, including based on immunological correlates of protection and data from trials in young children. [63]

Outbreak management in institutions includes rapid surveillance, isolation of cases, enhanced cleaning, and staff training. These measures have proven effective in reducing secondary cases and outbreak duration. [64]

Table. Practical preventive measures

Measure	Concrete actions
Hand hygiene	Wash with soap for at least 20 seconds after using the toilet and before eating
Disinfection	Chlorine solution 1000-5000 ppm, hold for 5 minutes
Food safety	Heat treatment of shellfish, cutting boards, cooling of finished dishes
Suspension from work	At least 48 hours after symptoms disappear
Flash control	Isolation, enhanced cleaning, information and training of staff

Forecast

In most patients, the disease is self-limiting and results in full recovery within a few days with prompt rehydration. Prognosis is determined by age, comorbidities, and access to medical care. [65]

The worst outcomes are associated with delayed rehydration in children and the elderly. Timely correction of fluid and electrolyte losses almost completely prevents life-threatening complications. [66]

There is a risk of post-infectious functional disorders, but the absolute values are moderate. Most symptoms regress over time with proper patient education and supportive therapy. [67]

In immunocompromised patients, the prognosis depends on control of the underlying condition, possible correction of immunosuppression, and access to supportive care. A multidisciplinary approach is required for this group. [68]

From a public health perspective, reliable hygienic and organizational measures can significantly limit outbreaks and reduce the burden on hospitals during the season. [69]

Table. Forecast factors

Factor	Influence
Age up to 5 years and over 65 years	Increased risk of dehydration and hospitalization
Associated diseases	Increased risk of complications
Time to start rehydration	The sooner, the better the outcome.
Immune status	In case of immunodeficiency, a protracted course is possible
Level of care organization	Reducing secondary cases and outbreak duration

FAQ

How long does contagiousness last after recovery?
The virus can be shed for weeks after symptoms disappear, so maintaining good hygiene and avoiding food handling for at least 48 hours remain critical. [70]

Can norovirus be treated with antibiotics?
No. It is a viral infection, so antibiotics are ineffective and not indicated. The main treatment is rehydration and symptomatic support. [71]

Are there effective antiviral drugs?
Specific agents for routine use have not yet been approved. Nitazoxanide and other candidates have been studied, but there is no convincing data for widespread use; targeted solutions through research are possible. [72]

Is there a vaccine?
Several platforms are being developed, but the most advanced candidate, HIL-214, was not effective in a large infant study. Development is ongoing, taking into account new immunological criteria. [73]

How to clean up after an episode of vomiting?
Use a chlorine solution containing 1000-5000 parts per million, leave it for at least 5 minutes, and clean off any visible debris and treat the extended area around the incident. Wash your hands with soap. [74]